Oncology

As of 26 April, 2022

Product Name	Mechanism	Target Disease	Development Stage					Country / Region	Licensor
			1	2	3	Filing	Approval
ONO-4059	BTK inhibitor	Primary central nervous system lymphoma						JP・KR・TW	In-house
								US
		Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma						JP
ONO-7475	Axl/Mer inhibitor	Acute leukemia						US	In-house
		Solid tumor ★						JP
		EGFR mutation-positive non-small cell lung cancer						JP
ONO-4685	PD-1 x CD3 bispecific antibody	T-cell lymphoma						US	In-house
ONO-4578	PG receptor (EP4) antagonist	Solid tumor・Gastric cancer ★						JP	In-house
		Colorectal cancer ★						JP
		Pancreatic cancer ★						JP
		Non-small cell lung cancer ★						JP
		Hormone receptor-positive, HER2-negative breast cancer						JP
ONO-7914	STING agonist	Solid tumor ★						JP	In-house

★Combination with Nivolumab

Other than oncology

As of 26 April, 2022

Product Name	Mechanism	Target Disease	Development Stage					Country / Region	Licensor
			1	2	3	Filing	Approval
ONO-4059	BTK inhibitor	Pemphigus						JP	In-house
		Generalized scleroderma						JP
ONO-2910	Enhancement of Schwann cell differentiation	Diabetic polyneuropathy						JP	In-house
ONO-4685	PD-1 x CD3 bispecific antibody	Autoimmune disease						EU	In-house
								JP	In-house
ONO-2808	S1P5 receptor agonist	Neurodegenerative disease						EU	In-house
								JP
ONO-7684	FXla inhibitor	Thrombosis						EU	In-house
ONO-2909	PG receptor (DP1) antagonist	Narcolepsy						JP	In-house